WO2023180953 - INHIBITORS OF HUMAN SLC7A3 FOR THE TREATMENT OF ENDOMETRIOSIS OR UTERINE FIBROIDS
National phase entry is expected:
Publication Number
WO/2023/180953
Publication Date
28.09.2023
International Application No.
PCT/IB2023/052814
International Filing Date
22.03.2023
Title **
[English]
INHIBITORS OF HUMAN SLC7A3 FOR THE TREATMENT OF ENDOMETRIOSIS OR UTERINE FIBROIDS
[French]
INHIBITEURS DE SLC7A3 HUMAIN POUR LE TRAITEMENT DE L'ENDOMÉTRIOSE OU DE FIBROMES UTÉRINS
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
Inventors
KUMAR, Janet M.
LAPING, Nicholas J.
Priority Data
63/322,874
23.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2198 | |
| EPO | Filing, Examination, Granting | 10821 | |
| Japan | Filing, Examination, Granting | 2325 | |
| South Korea | Filing, Examination, Granting | 2371 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,455
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to an inhibitor of human SLC7A3 for use in the treatment or prevention of endometriosis or uterine fibroids. Combination therapies are also described. In one aspect, the present disclosure relates to methods for targeting human SLC7A3 to treat or prevent endometriosis or uterine fibroids.[French]
La présente invention concerne un inhibiteur de SLC7A3 humain destiné à être utilisé dans le traitement ou la prévention de l'endométriose ou de fibromes utérins. L'invention concerne également des polythérapies. Selon un aspect, la présente invention concerne des procédés de ciblage de SLC7A3 humain pour traiter ou prévenir l'endométriose ou les fibromes utérins.